ViiV’s Tivicay is to become available in Europe in a new dispersible tablet form to treat children living with HIV. The joint venture, majority-owned by GlaxoSmithKline with Pfizer and Shionogi ...

Gilead is mounting a challenge against GlaxoSmithKline’s HIV drug, Tivicay, with its rival integrase inhibitor bictegravir. At the same time, GSK’s ViiV HIV unit hit back with data of its own ...